tradingkey.logo

Integra Lifesciences Holdings Corp

IART
11.490USD
-0.520-4.33%
Close 11/03, 16:00ETQuotes delayed by 15 min
894.32MMarket Cap
LossP/E TTM

Integra Lifesciences Holdings Corp

11.490
-0.520-4.33%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Integra Lifesciences Holdings Corp

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Integra Lifesciences Holdings Corp's Score

Industry at a Glance

Industry Ranking
70 / 210
Overall Ranking
166 / 4617
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 12 analysts
Hold
Current Rating
15.500
Target Price
+29.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Integra Lifesciences Holdings Corp Highlights

StrengthsRisks
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -1.78, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 73.60M shares, decreasing 24.86% quarter-over-quarter.
Held by Robert Olstein
Star Investor Robert Olstein holds 139.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 7.68, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 402.06M, representing a year-over-year increase of 5.57%, while its net profit experienced a year-over-year increase of 49.47%.

Score

Industry at a Glance

Previous score
7.68
Change
0

Financials

5.13

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.73

Operational Efficiency

10.00

Growth Potential

9.07

Shareholder Returns

7.49

Integra Lifesciences Holdings Corp's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 8.05, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -1.78, which is -6160.38% below the recent high of 107.70 and -16878.73% above the recent low of -301.73.

Score

Industry at a Glance

Previous score
8.05
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 70/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Integra Lifesciences Holdings Corp is 13.00, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts
Hold
Current Rating
15.500
Target Price
+29.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Integra Lifesciences Holdings Corp
IART
12
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.44, which is lower than the Healthcare Equipment & Supplies industry's average of 6.72. Sideways: Currently, the stock price is trading between the resistance level at 14.97 and the support level at 9.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.61
Change
-0.17

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.865
Neutral
RSI(14)
31.071
Neutral
STOCH(KDJ)(9,3,3)
17.678
Sell
ATR(14)
0.951
High Vlolatility
CCI(14)
-179.303
Sell
Williams %R
91.912
Oversold
TRIX(12,20)
0.009
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
13.260
Sell
MA10
14.557
Sell
MA20
14.497
Sell
MA50
14.632
Sell
MA100
13.697
Sell
MA200
16.559
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 94.48%, representing a quarter-over-quarter decrease of 17.64%. The largest institutional shareholder is The Vanguard, holding a total of 7.50M shares, representing 9.63% of shares outstanding, with 1.36% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
9.43M
-3.31%
TRU ST Partnership, L.P.
8.52M
--
The Vanguard Group, Inc.
Star Investors
7.50M
+0.46%
Rubric Capital Management LP
7.35M
+58.36%
Fuller & Thaler Asset Management Inc.
3.89M
-0.76%
Invesco Advisers, Inc.
3.18M
+1.66%
Dimensional Fund Advisors, L.P.
2.92M
+12.91%
State Street Investment Management (US)
2.83M
+2.88%
Boston Management and Research
2.74M
--
Paradigm Capital Management, Inc.
2.18M
+57.49%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 5.33, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.33
Change
0
Beta vs S&P 500 index
1.20
VaR
+3.85%
240-Day Maximum Drawdown
+58.08%
240-Day Volatility
+60.54%

Return

Best Daily Return
60 days
+8.63%
120 days
+8.63%
5 years
+25.10%
Worst Daily Return
60 days
-23.46%
120 days
-23.46%
5 years
-23.46%
Sharpe Ratio
60 days
-0.15
120 days
-0.23
5 years
-0.63

Risk Assessment

Maximum Drawdown
240 days
+58.08%
3 years
+81.60%
5 years
+85.48%
Return-to-Drawdown Ratio
240 days
-0.86
3 years
-0.32
5 years
-0.20
Skewness
240 days
-1.31
3 years
-1.14
5 years
-1.08

Volatility

Realised Volatility
240 days
+60.54%
5 years
+44.18%
Standardised True Range
240 days
+7.57%
5 years
+11.92%
Downside Risk-Adjusted Return
120 days
-27.23%
240 days
-27.23%
Maximum Daily Upside Volatility
60 days
+40.38%
Maximum Daily Downside Volatility
60 days
+62.85%

Liquidity

Average Turnover Rate
60 days
+1.71%
120 days
+1.52%
5 years
--
Turnover Deviation
20 days
+41.37%
60 days
+35.25%
120 days
+20.09%

Peer Comparison

Healthcare Equipment & Supplies
Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp
IART
7.15 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI